Who founded Exo Therapeutics?

Exo Therapeutics was founded by David Liu, PhD, Alan Saghatelian, PhD, David Liu, Alan Saghetelian.

Who are Exo Therapeutics's investors?

Exo Therapeutics's investors include Newpath Partners, CRV (Charles River Ventures), Nextech Invest, Raptor Group, Samsara BioCapital, Biotechnology Value Fund, Casdin Capital, Novartis Venture Fund.

How much funding has Exo Therapeutics raised?

Exo Therapeutics has disclosed $78M raised across 1 of its 2 known rounds.

Exo Therapeutics

9 known investors

Find your way into Exo Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Exo Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

Biotech Deep Tech Medical Devices

Founders & leadership

David Liu, PhDFounder

Alan Saghatelian, PhDCo-Founder

David Liu David Liu is a chemistry and genome editing researcher at Harvard University and the Broad Institute, as well as a Howard Hughes Medical Institute Investigator. He has founded or co-founded multiple biotechnology companies including Beam Therapeutics, Prime Medicine, Editas Medicine, and Exo Therapeutics, and has developed technologies including base editing and prime editing that are used in research and clinical applications.

Alan Saghetelian

Investors · 9

Newpath Partners✓ confirmed by Exo TherapeuticsBoston · $50K – $10M

How we know: the company's own site · funding news · the VCSheet dataset · Not right? Tell us

CRV (Charles River Ventures)listed by CRV (Charles River Ventures)Bay Area · $250K – $5M

How we know: CRV (Charles River Ventures)'s portfolio page · Not right? Tell us

Nextech Investlisted by Nextech InvestZurich · $648K – $3.2M

How we know: Nextech Invest's portfolio page · a partner's Signal profile · fiercebiotech.com · Not right? Tell us

Raptor Grouplisted by Raptor GroupMiami Beachvia James J. Pallotta · inferred

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · fiercebiotech.com · Not right? Tell us

Biotechnology Value FundreportedSan Francisco

How we know: fiercebiotech.com · Not right? Tell us

Casdin CapitalreportedNew York

How we know: funding news · fiercebiotech.com · Not right? Tell us

Novartis Venture FundreportedBasel · $5M – $25M

How we know: funding news · Not right? Tell us

Also in the syndicate · 1

Morningside

Funding

SEC filings, press & company announcements

$78M disclosed across 1 of 2 rounds · 2020–2021

$78Mseries BOct 2021 · 3 sources
BVF Partners, Casdin Capital, Morningside, Nextech Invest, Samsara Biocapital
Source ↗
Undisclosed amountSeries ADec 2020
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Exo Therapeutics went on to found or lead other companies.

David R. LiuFounded Chroma Medicine +3 Nagesh MahanthappaExecutive ChairFounded Scholar Rock

Related companies · 2

Exo ImagingExo is a company backed by leading venture capital and corporate investors focused on innovative technologies, with particular emphasis on healthcare, bioelectronic medicines, materials science, and deep technology solutions.

LexeotxLexeo is a clinical-stage genetic medicine company developing gene therapies that target the genetic causes of cardiovascular diseases. Based in New York City, it focuses on treatments for heart health and other genetic diseases regardless of prevalence.

Companies working in the same space as Exo Therapeutics.

In the news

Exo Therapeutics Launches with $25 Million Series A Financing to Unlock Intractable Drug Targets with Exosites - BioSpacebiospace.com · Dec 2020

Frequently asked questions

What does Exo Therapeutics do?: Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
Who founded Exo Therapeutics?: Exo Therapeutics was founded by David Liu, PhD, Alan Saghatelian, PhD, David Liu, Alan Saghetelian.
Who are Exo Therapeutics's investors?: Exo Therapeutics's investors include Newpath Partners, CRV (Charles River Ventures), Nextech Invest, Raptor Group, Samsara BioCapital, Biotechnology Value Fund, Casdin Capital, Novartis Venture Fund.
How much funding has Exo Therapeutics raised?: Exo Therapeutics has disclosed $78M raised across 1 of its 2 known rounds.